Evidence map›Paper›PMID 33839143›Full record

ArticleExperimental neurology2021

Characterization of nonmotor behavioral impairments and their neurochemical mechanisms in the MitoPark mouse model of progressive neurodegeneration in Parkinson's disease.

Monica R Langley, Shivani Ghaisas, Bharathi N Palanisamy, Muhammet Ay, Huajun Jin, Vellareddy Anantharam, Arthi Kanthasamy, Anumantha G Kanthasamy

Open access · greenAbstract read
In one paragraph

Article in Experimental neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Chronobiology of Parkinson's disease: Past, present and future.The European journal of neuroscience · 2023
    Review
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Monica R LangleyParkinson Disorders Research Program, Iowa Center for Advanced Neurotoxicology, Department of Biomedical Sciences, Iowa State University, Ames, IA 50011, United States of America.
Shivani GhaisasParkinson Disorders Research Program, Iowa Center for Advanced Neurotoxicology, Department of Biomedical Sciences, Iowa State University, Ames, IA 50011, United States of America.
Bharathi N PalanisamyParkinson Disorders Research Program, Iowa Center for Advanced Neurotoxicology, Department of Biomedical Sciences, Iowa State University, Ames, IA 50011, United States of America.
Muhammet AyParkinson Disorders Research Program, Iowa Center for Advanced Neurotoxicology, Department of Biomedical Sciences, Iowa State University, Ames, IA 50011, United States of America.
Huajun JinParkinson Disorders Research Program, Iowa Center for Advanced Neurotoxicology, Department of Biomedical Sciences, Iowa State University, Ames, IA 50011, United States of America.
Vellareddy AnantharamParkinson Disorders Research Program, Iowa Center for Advanced Neurotoxicology, Department of Biomedical Sciences, Iowa State University, Ames, IA 50011, United States of America.
Arthi KanthasamyParkinson Disorders Research Program, Iowa Center for Advanced Neurotoxicology, Department of Biomedical Sciences, Iowa State University, Ames, IA 50011, United States of America.
Anumantha G KanthasamyParkinson Disorders Research Program, Iowa Center for Advanced Neurotoxicology, Department of Biomedical Sciences, Iowa State University, Ames, IA 50011, United States of America. Electronic address: akanthas@iastate.edu.
Iowa State University · US

Funding

Protein Aggregation and Inflammasome Signaling in Manganese Neurotoxicity.R01ES026892 · NIEHS · UNIVERSITY OF GEORGIA · PI KANTHASAMY, ANUMANTHA GOUNDER · 2016 to 2020
$2.0M
Neuroinflammation and microglial Kv1.3 in Parkinsons diseaseR01NS100090 · NINDS · UNIVERSITY OF GEORGIA · PI KANTHASAMY, ANUMANTHA GOUNDER · 2017 to 2021
$1.9M
Novel Mechanisms of Pesticide-Induced NeurotoxicityR01ES027245 · NIEHS · UNIVERSITY OF GEORGIA · PI KANTHASAMY, ANUMANTHA GOUNDER · 2017 to 2021
$1.7M
Exosomes and Neuroinflammation in Parkinsons DiseaseR01NS088206 · NINDS · IOWA STATE UNIVERSITY · PI KANTHASAMY, ARTHI · 2015 to 2019
$1.6M
NIEHS NIH HHS R01 ES026892NIEHS NIH HHS R01 ES027245NINDS NIH HHS R01 NS088206NINDS NIH HHS R01 NS100090
6 · The paper itself

Abstract

Mitochondrial dysfunction has been implicated as a key player in the pathogenesis of Parkinson's disease (PD). The MitoPark mouse, a transgenic mitochondrial impairment model developed by specific inactivation of TFAM in dopaminergic neurons, spontaneously exhibits progressive motor deficits and neurodegeneration, recapitulating several features of PD. Since nonmotor symptoms are now recognized as important features of the prodromal stage of PD, we comprehensively assessed the clinically relevant motor and nonmotor deficiencies from ages 8-24 wk in both male and female MitoPark mice and their littermate controls. As expected, motor deficits in MitoPark mice began around 12-14 wk and became severe by 16-24 wk. Interestingly, MitoPark mice exhibited olfactory deficits in the novel and social scent tests as early as 10-12 wk as compared to age-matched littermate controls. Additionally, male MitoPark mice showed spatial memory deficits before female mice, beginning at 8 wk and becoming most severe at 16 wk, as determined by the Morris water maze. MitoPark mice between 16 and 24 wk spent more time immobile in forced swim and tail suspension tests, and made fewer entries into open arms of the elevated plus maze, indicating a depressive and anxiety-like phenotype, respectively. Importantly, depressive behavior as determined by immobility in forced swim test was reversible by antidepressant treatment with desipramine. Neurochemical and mechanistic studies revealed significant changes in CREB phosphorylation, BDNF, and catecholamine levels as well as neurogenesis in key brain regions. Collectively, our results indicate that MitoPark mice progressively exhibit deficits in olfactory discrimination, cognitive learning and memory, and anxiety- and depression-like behaviors as well as key neurochemical signaling associated with nonmotor deficits in PD. Thus, MitoPark mice can serve as an invaluable model for studying nonmotor deficits in addition to studying the motor deficits related to pathology in PD.

Indexed as

Disease Models, AnimalDisease ProgressionAnimalsDNA-Binding ProteinsFemaleMaleMiceMice, TransgenicMitochondriaMitochondrial ProteinsNeurodegenerative DiseasesParkinson DiseaseTranscription FactorsDNA-Binding ProteinsMitochondrial Proteinsmitochondrial transcription factor ATranscription FactorsBehaviorMitoParkNonmotorParkinson's disease

Identifiers

PMID33839143
PMCPMC9797183
OpenAlexW3154962341

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.